AIxCrypto Holdings, Inc.

Listed Company

AIXCCIK 0001460702NasdaqNon-AcceleratedSmaller ReportingFinance ServicesDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-16.97M

Total Assets

$31.28M

Equity

$27.95M

Shares Out

20.23M

Op. Cash Flow

$-6.95M

Business

AIxCrypto Holdings, Inc. is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers. Its principal programs include QN-302, a G-quadruplex-selective small molecule now in a Phase 1a clinical trial, and a preclinical Pan‑RAS small molecule inhibitor program; the company also has a co-development/funding arrangement related to Marizyme’s DuraGraft vascular conduit solution and holds a minority interest in NanoSynex. Key business activities comprise clinical drug development, in‑licensing and collaborations, and strategic investments and out‑licensing efforts. Its activities are conducted primarily through U.S. clinical trial sites, international in‑licensed patent territories, CROs, and commercialization or co‑development partners.

Summary from filing dated 2025-06-30

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
General and administrative	9	4	6	10	12
Research and development	184,796	1	5	4	12
Credit loss expense - short-term note receivable	4	360,000	—	—	—
Total expenses	13	6	11	15	28
LOSS FROM OPERATIONS	−13	−6	−11	−15	−23
Gain on change in fair value of warrant liabilities	−127,297	−415,810	—	—	—
Gain on change in fair value of derivative liabilities	—	−191,068	—	−907,203	−5
Gain on change in fair value of convertible debt	−37,707	—	—	—	—
Interest expense	988,500	908,943	2	—	—
Interest income	−742,018	−128,795	—	—	—
Loss on issuance of convertible debt	91,943	358,279	—	—	—
Net loss on digital assets	4	—	—	—	—
Gain on voluntary conversion of convertible debt into common stock	—	−56,010	1	—	—
Loss on debt extinguishment	—	56,997	625,653	—	—
Loss on monthly redemptions of convertible debt into common stock	—	208,852	—	—	—
Gain on settlements of accounts payable	—	−348,305	—	—	—
Other expense (income), net	2,252	−1,946	−38,994	—	−5,446
Total other expense (income), net	4	391,137	1	−872,806	−5
LOSS BEFORE PROVISION FOR INCOME TAXES	−17	−6	−12	−14	−18
PROVISION FOR INCOME TAXES	0	6,334	−4,793	7,000	5,000
NET LOSS FROM CONTINUING OPERATIONS	−17	−6	−12	−14	—
Loss on disposal of discontinued operations, net of tax	—	−100,000	−602,232	—	—
LOSS FROM DISCONTINUED OPERATIONS	—	−100,000	−1	−7	—
NET LOSS	−17	−6	−13	−19	−18
Deemed dividend arising from preferred stock and warrant down-round provision	−3	−87,604	—	—	—
Net loss attributable to shareholders	−20	−6	−13	—	—
Net loss per common share, basic - continuing operations	−8.11	−17.27	−122.93	−3.62	—
Net loss per common share, diluted - continuing operations	−8.11	−17.27	−122.93	−3.62	—
Net loss per common share, basic - discontinued operations	—	−0.28	−9.32	−1.24	—
Net loss per common share, diluted - discontinued operations	—	−0.28	−9.32	−1.24	—
Total net loss per common share, basic	−8.11	−17.55	−132.25	−4.85	−6.1
Total net loss per common share, diluted	−8.11	−17.55	−132.25	—	—
Weighted-average number of shares outstanding, basic	2	361,587	5	4	3
Weighted-average number of shares outstanding, diluted	2	361,587	101,454	4	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	19	1	401,803	—	—
Digital assets	10	—	—	—	—
Prepaid expenses and other current assets	1	1	764,964	1	1
Short-term notes receivable, net of allowance for credit losses of $4.6 million and $360,000 at December 31, 2025 and 2024, respectively	343,060	2	—	—	—
Total current assets	31	5	1	11	21
Intangible assets	314,727	—	—	—	—
Total non-current assets	325,076	2,000	—	—	—
Total Assets	31	5	2	19	23
Accounts payable	1	2	2	619,568	886,224
Accrued expenses and other current liabilities	136,234	170,243	560,006	864,559	2
Warrant liabilities	141,878	269,175	54,600	—	—
Convertible debt	142,236	—	—	—	—
Total current liabilities	3	2	4	9	5
Commitments and Contingencies (Note 10)	—	—	—	—	—
Common stock, $0.001 par value; 225,000,000 shares authorized; 5,160,383 and 736,431 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	69,738	65,314	43,262	42,110	35,290
Additional paid-in capital	136	120	115	111	101
Accumulated deficit	−140	−123	−117	−103	−85
Total Stockholders Equity	28	3	−2	7	17
Total Liabilities & Stockholders Equity	31	5	2	19	23

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Loss from discontinued operations, net of tax	—	−100,000	−1	−7	—
Stock-based compensation	268	128,059	1	5	5
Change in fair value of warrant liabilities	−127,297	−415,810	−2	−906,345	−5
Gain on voluntary conversion of convertible debt	—	−56,010	—	—	—
Legal expenses deducted from issuance of convertible debt	20,000	—	—	—	—
Issuance of common stock to consultant	325,635	—	—	—	—
Provision for credit losses of short-term note receivable	4	360,000	—	—	—
Accrued interest on short-term note receivable	−617,868	−113,292	—	—	—
Interest expense	988,500	—	—	—	—
Payments made with digital assets	39,968	—	—	—	—
Accretion of discount on convertible debt	—	615,534	1	—	—
Loss on issuance of convertible debt	91,943	358,279	—	—	—
Loss on change in fair value of convertible debt	−37,707	—	—	—	—
Fair value of warrant modification for professional services	—	12,036	7,945	67,370	—
Prepaid expenses and other assets	462,364	−219,774	−264,741	−126,985	1
Accounts payable	−350,246	−445,141	2	−43,440	385,455
Accrued expenses and other current liabilities	1	−118,669	−227,101	−472,441	1
Net cash used in operating activities	−7	−6	−10	−13	−15
Issuance of short-term note receivable	−2	−2	—	—	—
Purchase of digital assets	−17	—	—	—	—
Sales of digital assets	3	—	—	—	—
Purchase of intangible assets	−93,416	—	—	—	−6,893
Net cash provided by investing activities - discontinued operations	—	350,000	4	−183,763	—
Net cash used in investing activities	−16	−2	4	−183,763	−141,364
Proceeds from the issuance of convertible debt	200,000	1	—	—	—
Proceeds from issuance of common shares and prefunded warrants in public offering	—	3	—	—	—
Repayment of convertible debt	−132,000	−499,021	—	—	—
Repayment of promissory notes	−4	−2	—	—	—
Proceeds from warrant exercises	—	415,981	—	7,173	459,476
Proceeds from issuance of promissory notes	3	2	—	—	—
Net cash provided by financing activities - continuing operations	41	9	−550,000	3	—
Net cash provided by financing activities - discontinued operations	—	—	—	—	—
Net cash provided by financing activities	41	9	−550,000	3	8
Net change in cash and cash equivalents	18	772,805	−7	−11	—
Interest	1	92,838	—	—	1,233
Taxes	—	5,522	5,571	5,571	5,133
Voluntary conversion of convertible debt into preferred stock	—	1	—	—	—
Monthly redemption of convertible debt into common stock	—	903,329	254,316	—	—
Voluntary conversion of convertible debt into common stock	—	735,083	1	—	—
Deemed dividend arising from warrant and preferred shares down-round provision	3	87,604	—	—	—
Exchange of derivative liability for warrant and convertible debt	—	675,625	—	—	—
Restricted share settlements issued to former board members	—	142,351	—	—	—
Warrants reclassified to equity from liabilities	—	197,456	—	—	—
Warrants reclassified to liabilities from equity	—	262,259	—	—	—
Issuance of warrants to placement agent	5	—	—	—	—
Issuance of common stock for the conversion of Series A-2 and Series A-3 preferred shares	9	—	—	2	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro